Georgia's Online Cancer Information Center


back
Search Trials

All Cancer Clinical Trials in Georgia

Search Trials
All Cancer Clinical Trials
NCI ID Cancer Type Trial Name
Clinical Trial data last updated Sep 20, 2022.
NCI ID Cancer Type Trial Name
(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
Cancer Type
Leukemia
NCT ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05186753
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03800693
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT03849118
Protocol IDs
89Zr-TLX250-003
NCI-2020-02184
9-ING-41 in Patients With Advanced Cancers
Cancer Type
Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT03678883
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Neuroblastoma
NCT ID
NCT04239092
Protocol IDs
1902
NCI-2020-04584
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Cancer Type
Head and Neck Cancer
NCT ID
NCT04534205
Protocol IDs
BNT113-01
NCI-2021-03177
2020-001400-41
A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04115631
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03861793
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04505826
Protocol IDs
OP-1250-001
NCI-2020-13877
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Cancer Type
Lung Cancer, Melanoma
NCT ID
NCT04543188
Protocol IDs
C4471001
NCI-2020-08201
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Cancer Type
Liver Cancer / Hepatoblastoma
NCT ID
NCT02954094
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Piedmont Hospital - Atlanta
Atlanta
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT01351545
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT00078598
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT01630733
Protocol IDs
TV1011-LC-303
2012-002447-14
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCT ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03978689
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
A Phase 1 Study of Engineered Donor Grafts (OrcaGraft/Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03802695
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Cancer Type
Lung Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT03600883
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCT ID
NCT03420183
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT02723994
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)
Cancer Type
Lung Cancer
NCT ID
NCT05060016
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Cancer Type
Leukemia
NCT ID
Protocol IDs
NCT01980875
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Kidney Cancer
NCT ID
NCT01772004
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Head and Neck Cancer
NCT ID
NCT01772004
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Breast Cancer
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Melanoma
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Ovarian Cancer
NCT ID
NCT01772004
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Mesothelioma
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Adrenal Cancer
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Bladder Cancer
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Solid Tumor
NCT ID
NCT01772004
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma
NCT ID
NCT02339571
Protocol IDs
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Phase III Double Blind Study On The Efficacy of Topical Aloe Vera Gel on Irradiated Breast Tissue
Cancer Type
Breast Cancer
NCT ID
Protocol IDs
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Cancer Type
Colon/Rectal Cancer
NCT ID
Protocol IDs
NCT02563002
A Phase III, Single-arm, Open Label, Single Study of Topical Application of a 2 Step Radiaderm Advanced Skincare System containing LactokineTM Fluid on Radiation Dermatitis in Breast Cancer Patients Treated with Adjuvant Whole Breast Radiation Therapy
Cancer Type
Breast Cancer
NCT ID
Protocol IDs
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Cancer Type
Breast Cancer
NCT ID
NCT05104866
Protocol IDs
D9268C00001
NCI-2021-14072
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03561220
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCT ID
Protocol IDs
AMG 011 20170758
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCT ID
Protocol IDs
AMG 011 20170758
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and other Patients
Cancer Type
Multiple Primaries
NCT ID
Protocol IDs
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer
Cancer Type
Multiple Primaries
NCT ID
Protocol IDs
A Registry of Cesium-131 Brachytherapy Plus Sub- lobar Resection for Early Stage Lung Cancer
Cancer Type
Lung Cancer
NCT ID
Protocol IDs
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04409301
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT04035434
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Cancer Type
Breast Cancer
NCT ID
NCT00781612
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCT ID
NCT03374085
Protocol IDs
Treatment Sites (1)
Emory Clinic
Atlanta
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Cancer Type
Breast Cancer
NCT ID
NCT04873362
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Cancer Type
Breast Cancer
NCT ID
NCT04961996
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04546009
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCT ID
NCT04191499
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04712097
Protocol IDs
GO42909
NCI-2021-09247
2020-005239-53
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04910568
Protocol IDs
GO42552
NCI-2021-07543
2021-000238-33
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors that Cannot be Removed by Surgery
Cancer Type
Unknown Primary
NCT ID
NCT04195399
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Cancer Type
Bone Tumor
NCT ID
NCT03706365
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03767244
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCT ID
NCT04513925
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Cancer Type
Unknown Primary
NCT ID
NCT04710576
Protocol IDs
SNDX-6352-0504
NCI-2021-01333
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04586231
Protocol IDs
6482-011
MK-6482-011
NCI-2020-11420
2020-002075-35
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03400332
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCT ID
NCT04943900
Protocol IDs
CA102-003
NCI-2021-09090
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Cancer Type
Hodgkin Lymphoma
NCT ID
NCT01716806
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04404660
Protocol IDs
FELIX (AUTO1-AL1)
AUTO1-AL1
NCI-2020-04370
2019-001937-16
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCT ID
NCT04322318
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCT ID
NCT05091346
Protocol IDs
E7386-G000-201
NCI-2022-02226
2021-001568-10
KEYNOTE-C83
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT04607421
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT03288545
Protocol IDs
Treatment Sites (2)
Piedmont Cancer Institute
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Engineered Donor Grafts (TregGraft/Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Leukemia
NCT ID
NCT04013685
Protocol IDs
TRGFT-201
NCI-2019-08529
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04083976
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04172675
Protocol IDs
CR108699
NCI-2020-00674
42756493BLC2003
2019-002449-39
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04764474
Protocol IDs
2020-306-GLOB1
NCI-2021-03247
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04762602
Protocol IDs
2020-306-GLOB2
NCI-2021-01982
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type
Unknown Primary
NCT ID
NCT05263999
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05347485
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04133636
Protocol IDs
CR108581
2018-004124-10
68284528MMY2003
NCI-2019-07363
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05022849
Protocol IDs
CR108972
NCI-2021-12359
75229414MPC1001
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Cancer Type
Breast Cancer
NCT ID
NCT04188548
Protocol IDs
17502
2019-003581-41
J2J-MC-JZLA
NCI-2020-06404
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04647487
Protocol IDs
17575
NCI-2021-00207
J2J-MC-JZLB
2020-002810-42
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03215030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT04026412
Protocol IDs
CA209-73L
NCI-2019-08594
2019-001222-98
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Cancer Type
Bone Tumor
NCT ID
NCT04100018
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT03740529
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04736706
Protocol IDs
6482-012
MK-6482-012
NCI-2021-05629
2020-002216-52
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Cancer Type
Lymphoma, Neuroblastoma
NCT ID
NCT02332668
Protocol IDs
3475-051
NCI-2015-00528
2014-002950-38
A Study of RGX-104 in Patients With Advanced Solid Malignancies
Cancer Type
Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer
NCT ID
NCT02922764
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type
Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT04211337
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type
Leukemia
NCT ID
NCT04065399
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCT ID
NCT03656718
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Cancer Type
Breast Cancer
NCT ID
NCT04247126
Protocol IDs
SY-5609-101
NCI-2020-03935
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04776018
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05050097
Protocol IDs
CR108946
NCI-2021-13605
2020-004502-55
64407564MMY1004
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
Cancer Type
Neuroendocrine Tumor, Prostate Cancer , Unknown Primary
NCT ID
NCT04702737
Protocol IDs
20200040
NCI-2021-08862
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04722146
Protocol IDs
CR108927
NCI-2021-02225
64007957MMY1004
2020-004404-33
A Study of the Drugs Selumetinib versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor
NCT ID
NCT03871257
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCT ID
NCT04166409
Protocol IDs
ACNS1833
ACNS1833
NCI-2019-07600
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Leukemia, Neuroblastoma, Non-Hodgkin Lymphoma
NCT ID
NCT03236857
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
Cancer Type
Breast Cancer
NCT ID
NCT04740918
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCT ID
NCT02817633
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Cancer Type
Breast Cancer
NCT ID
NCT04539938
Protocol IDs
SGNTUC-025
NCI-2020-08177
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Cancer Type
Breast Cancer
NCT ID
NCT03975647
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
A Study of VS-6766 and VS-6766 + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT04620330
Protocol IDs
VS-6766-202
NCI-2021-01997
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Cancer Type
Multiple Myeloma
NCT ID
NCT04123418
Protocol IDs
CWVT078A12101
NCI-2021-09189
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Cancer Type
Breast Cancer, Lung Cancer
NCT ID
NCT03845166
Protocol IDs
XL092-001
NCI-2019-03738
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Cancer Type
Head and Neck Cancer
NCT ID
NCT03752398
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Cancer Type
Cervical Cancer
NCT ID
NCT05032040
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Cancer Type
Lung Cancer, Pancreatic Cancer
NCT ID
NCT02912949
Protocol IDs
MCLA-128-CL01
NCI-2019-06025
2014-003277-42
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioma with Elevated Mutational Burden
Cancer Type
Brain & Spinal Cord Tumor
NCT ID
NCT04145115
Protocol IDs
A071702
A071702
NCI-2019-07242
A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT05002569
Protocol IDs
CA224-098
NCI-2022-02119
2021-001641-13
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03287908
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Lung Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type
Germ Cell Tumor
NCT ID
NCT04192344
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type
Leukemia
NCT ID
NCT04293562
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
Cancer Type
Unknown Primary
NCT ID
NCT04934670
Protocol IDs
BMT CTN 2002
NCI-2021-14060
2021-000343-53
5U24HL138660-02
XEN-TG-005
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Cancer Type
Melanoma
NCT ID
NCT04511013
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
A Study to Compare Treatments for a Type of Kidney Cancer called TFE/Translocation Renal Cell Carcinoma (tRCC)
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT03595124
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type
Ovarian Cancer
NCT ID
NCT04251052
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT02773030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03989414
Protocol IDs
CC-92480-MM-002
NCI-2019-04130
2018-004767-31
U1111-1233-5619
A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Cancer Type
Breast Cancer, Esophogeal Cancer, Head and Neck Cancer, Stomach/ Gastric Cancer
NCT ID
NCT04225117
Protocol IDs
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type
Sarcoma
NCT ID
NCT04554914
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type
Bile Duct Cancer
NCT ID
NCT03656536
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Lung Cancer, Solid Tumor
NCT ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Cancer Type
Multiple Myeloma
NCT ID
NCT04045028
Protocol IDs
Treatment Sites (1)
Emory Clinic
Atlanta
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Gynecologic Cancers, Ovarian Cancer, Prostate Cancer
NCT ID
NCT04972981
Protocol IDs
ADCT-901-101
NCI-2021-10797
2021-002292-19
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
Cancer Type
Unknown Primary
NCT ID
NCT03763318
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
A Study to Examine How Often (Every 5 Years or 10 Years) a Colonoscopy Should be Done in Participants Who Had One or Two Small Growths of Tissue Removed from Their Colon
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT05080673
Protocol IDs
NRG-CC005
NRG-CC005
NRG-CC005
NCI-2020-00733
A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03914625
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Cancer Type
Breast Cancer
NCT ID
NCT04946864
Protocol IDs
APG2575XU103
NCI-2021-11630
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).
Cancer Type
Lung Cancer
NCT ID
NCT04429087
Protocol IDs
1438-0001
NCI-2021-01392
2019-000729-31
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT03776071
Protocol IDs
DB102-01
NCI-2020-13730
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCT ID
NCT03970447
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer
NCT ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT04380740
Protocol IDs
20-227
NCI-2022-03010
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Neuroblastoma, Sarcoma
NCT ID
NCT02644460
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCT ID
NCT02582697
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCT ID
NCT03067181
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Actuate 1901: 9-ING-41 in Myelofibrosis
Cancer Type
Leukemia
NCT ID
NCT04218071
Protocol IDs
1901
NCI-2020-01824
Additional Support Program via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Cancer Type
Breast Cancer
NCT ID
NCT04379570
Protocol IDs
A191901
A191901
A191901
NCI-2020-02479
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03391778
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary, Urethral Cancer
NCT ID
NCT02122172
Protocol IDs
IRB13-0540
NCI-2014-00859
13-0540
Alisertib Alone or in Combination with Chemotherapy and Radiation Therapy in Treating Younger Patients with Recurrent, Progressive, or Newly Diagnosed Central Nervous System Atypical Teratoid Rhabdoid Tumors or Extra-Central Nervous System Malignant Rhabdoid Tumors
Cancer Type
Brain & Spinal Cord Tumor
NCT ID
NCT02114229
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT04920383
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03601078
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type
Cancer Control
NCT ID
NCT04462302
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
An Internet-Based Program to Help Cancer Survivors Manage Pain, IMPACTS Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04462302
Protocol IDs
WF-1901
WF-1901
WF-1901
NCI-2020-02315
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04660812
Protocol IDs
ARC-9
NCI-2021-02881
2020-005386-13
An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Cancer Type
Adrenal Cancer, Neuroblastoma
NCT ID
NCT01590680
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type
Pancreatic Cancer
NCT ID
NCT04858334
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
ASCO Survey on COVID-19 in Oncology (ASCO) Registry
Cancer Type
COVID-19, Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT04659135
Protocol IDs
Pro00014181
NCI-2021-00737
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Cancer Type
Leukemia
NCT ID
NCT03935555
Protocol IDs
PU-H71-01-003
NCI-2019-03010
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04105010
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Cancer Type
Stomach/ Gastric Cancer
NCT ID
NCT04592913
Protocol IDs
D910GC00001
NCI-2021-01109
2019-001555-40
Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCT ID
NCT03600701
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Atezolizumab in Treating Patients with Cancer following Adoptive Cell Transfer
Cancer Type
Hematopoietic Malignancies
NCT ID
NCT02862275
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Atlanta
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients with Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma
Cancer Type
Cancer-Related Syndrome
NCT ID
NCT03321643
Protocol IDs
Treatment Sites (2)
Radiation Oncology Associates
Augusta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
AWAKE Mobile Application and Coaching Phone Calls in Improving Health-Promoting Behaviors in Adolescent Cancer Survivors and Their Guardians
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT03564587
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03927027
Protocol IDs
A221702
A221702
A221702
NCI-2018-02445
AYA-RISE for the Improvement of Cancer Risk Communication and Decision-Making in Adolescents and Young Adults with Cancer Risk Syndromes
Cancer Type
Cancer-Related Syndrome
NCT ID
NCT04323774
Protocol IDs
20-003
NCI-2020-03811
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Cancer Type
Bile Duct Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT02568267
Protocol IDs
Treatment Sites (2)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04729608
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Battery Powered Drill versus Conventional Methods in Comparing Quality of Bone Marrow Biopsy, Convenience, and Pain Control in Patients with Plasma Cell Disorders
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03078452
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05208307
Protocol IDs
Winship5382-21
NCI-2021-08385
STUDY00003092
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04264702
Protocol IDs
20-041-NCP
NCI-2020-03933
Best Supportive Care with or without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 Infection
Cancer Type
COVID-19
NCT ID
NCT04433949
Protocol IDs
RAD5049-20
NCI-2020-04061
STUDY00000781
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT05387915
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type
Lung Cancer
NCT ID
NCT03851445
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Biopsy of Breast after Chemotherapy in Predicting Pathologic Response in Patients with Breast Cancer Undergoing Breast Conserving Surgery
Cancer Type
Breast Cancer
NCT ID
NCT03188393
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type
Non-Hodgkin Lymphoma
NCT ID
NCT03114865
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Blue Light Cystoscopy With Cysview® Registry
Cancer Type
Bladder Cancer
NCT ID
NCT02660645
Protocol IDs
BLCCR-001
NCI-2018-00299
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT04258943
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Brentuximab Vedotin and Nivolumab in Treating Patients with Early Stage Classic Hodgkin Lymphoma
Cancer Type
Hodgkin Lymphoma
NCT ID
NCT03712202
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT01896999
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03534804
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT03541902
Protocol IDs
2017-0725
NCI-2018-01041
Cabozantinib, Nivolumab, and Ipilimumab for the Treatment of Metastatic Non-clear Cell Renal Cell Cancer
Cancer Type
Kidney Cancer
NCT ID
NCT04413123
Protocol IDs
19-789
NCI-2020-11407
Cancer Care Delivery in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03204916
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Carboplatin and Paclitaxel with or without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT02876107
Protocol IDs
2016-0177
NCI-2017-00619
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03756896
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Caris Biorepository Research Protocol
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCT ID
NCT01499394
Protocol IDs
Treatment Sites (1)
Southeastern Urology Associates - Macon
Macon
Ginger Safford, RN
478-742-0932
CAR-T Long Term Follow Up (LTFU) Study
Cancer Type
Unknown Primary
NCT ID
NCT02445222
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04455750
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
CD40 Agonistic Monoclonal Antibody APX005M in Treating Pediatric Patients with Recurrent or Refractory Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT03389802
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04428671
Protocol IDs
Winship4851-19
NCI-2019-07373
IRB00115160
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05274763
Protocol IDs
EU5492-21
NCI-2022-00233
STUDY00003563
Chemoradiotherapy with or without Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer
NCT ID
NCT03775265
Protocol IDs
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975